Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search)
we decrease » _ decrease (Expand Search), mean decrease (Expand Search), teer decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search)
we decrease » _ decrease (Expand Search), mean decrease (Expand Search), teer decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
2101
-
2102
One-step synthesis of magnetic-TiO<sub>2</sub>-nanocomposites with high iron oxide-composing ratio for photocatalysis of rhodamine 6G
Published 2019“…With the same composing ratio of 0.5 and 0.35 (Fe:Ti, mole:mole), we prepared two types of magnetic-TiO<sub>2</sub>-nanocomposites as one-step synthesized Fe<sub>x</sub>O<sub>y</sub>-composed TiO<sub>2</sub> (Fe<sub>x</sub>O<sub>y</sub>/TiO<sub>2</sub>-0.5 and Fe<sub>x</sub>O<sub>y</sub>/TiO<sub>2</sub>-0.35) and two-step synthesized core-shell Fe<sub>x</sub>O<sub>y</sub>@TiO<sub>2</sub> (Fe<sub>x</sub>O<sub>y</sub>@TiO<sub>2</sub>-0.5 and Fe<sub>x</sub>O<sub>y</sub>@TiO<sub>2</sub>-0.35), and tested their performance in rhodamine 6G (R6G) photodegradation. …”
-
2103
-
2104
-
2105
Systemic ODQ administration improves stepping performance in chronic MPTP-treated mice.
Published 2013“…(<b>d</b>) Time course showing the effect of a single s.c. injection of vehicle and ODQ (5 and 10 mg/kg) on MPTP-induced stepping deficits (n = 5–7 mice per group). …”
-
2106
-
2107
-
2108
-
2109
3‑Hydroxyquinolin-2-Ones Act as Dual Inhibitors of Ferroptosis and Monoamine Oxidase B: Reducing Alzheimer’s Disease-Related Amyloid Precursor Protein and Hyperphosphorylated Tau I...
Published 2025“…Compound <b>21d</b> emerged as a promising candidate, exhibiting potent and selective MAO-B inhibitory activity (IC<sub>50</sub> = 87.47 nM, SI > 229), as well as excellent antiferroptosis activity through modulation of the iron metabolic pathway and GSH-GPX4 axis in vitro<i>.…”
-
2110
Addressing a Trapped High-Energy Water: Design and Synthesis of Highly Potent Pyrimidoindole-Based Glycogen Synthase Kinase-3β Inhibitors
Published 2021“…Here, by addressing a high-energy water, we improved the IC<sub>50</sub> value of our co-crystallized glycogen synthase kinase-3β (GSK-3β) inhibitor by nearly two orders of magnitude. …”
-
2111
Addressing a Trapped High-Energy Water: Design and Synthesis of Highly Potent Pyrimidoindole-Based Glycogen Synthase Kinase-3β Inhibitors
Published 2021“…Here, by addressing a high-energy water, we improved the IC<sub>50</sub> value of our co-crystallized glycogen synthase kinase-3β (GSK-3β) inhibitor by nearly two orders of magnitude. …”
-
2112
Twenty-two identified and replicated loci and their overlap with associations to metabolic traits and clinical phenotypes.
Published 2015“…<p><sup>a</sup> SNP with the strongest association to targeted metabolic traits (“lead SNP”)</p><p><sup>b</sup> SNP with the strongest association to non-targeted metabolic traits</p><p><sup>c</sup> manually added to the list of most plausible candidate genes derived by evidence-based selection</p><p><sup>d</sup> additional candidates match to other non-targeted traits that also associate with the lead SNP</p><p><sup>e</sup> results from GWAS (<i>P</i> < 5.0×10<sup>−8</sup>)</p><p><sup>f</sup> mutations determined in clinical studies</p><p>For each locus, we selected all variants that displayed genome-wide significant association signals to metabolic traits in the SHIP-0 cohort. …”
-
2113
-
2114
-
2115
-
2116
-
2117
-
2118
-
2119
-
2120